TY - JOUR
KW - Alcohol
KW - Alcoholism/complications/drug therapy
KW - British Columbia
KW - Chicago
KW - Delayed-Action Preparations/adverse effects/therapeutic use
KW - Extended-release naltrexone
KW - Feasibility Studies
KW - Female
KW - HIV
KW - HIV Infections/complications
KW - Humans
KW - Injection drug use
KW - Male
KW - Middle Aged
KW - Naltrexone/adverse effects/therapeutic use
KW - Narcotic Antagonists/adverse effects/therapeutic use
KW - opioid-related disorders
KW - Opioid-Related Disorders/complications/drug therapy
KW - Pilot Projects
KW - Randomized Clinical Trial
KW - Treatment Outcome
AU - P. T. Korthuis
AU - P. J. Lum
AU - P. Vergara-Rodriguez
AU - K. Ahamad
AU - E. Wood
AU - L. E. Kunkel
AU - N. L. Oden
AU - R. Lindblad
AU - J. L. Sorensen
AU - V. Arenas
AU - D. Ha
AU - R. N. Mandler
AU - D. McCarty
AU - CTN-0055 CHOICES Investigators
A1 - 
BT - Addiction (Abingdon, England)
C5 - Opioids & Substance Use; Healthcare Disparities
CP - 6
CY - England
DO - 10.1111/add.13753
IS - 6
JF - Addiction (Abingdon, England)
PB - Society for the Study of Addiction
PP - England
PY - 2017
SN - 1360-0443; 0965-2140
SP - 1036
EP - 1044
EP - 
T1 - Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
T2 - Addiction (Abingdon, England)
TI - Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
U1 - Opioids & Substance Use; Healthcare Disparities
U2 - 28061017
U3 - 10.1111/add.13753
VL - 112
VO - 1360-0443; 0965-2140
Y1 - 2017
ER -